Pain assessment: the advantages of using pain scales in lysosomal storage diseases
- PMID: 12572842
- DOI: 10.1111/j.1651-2227.2002.tb03109.x
Pain assessment: the advantages of using pain scales in lysosomal storage diseases
Abstract
Routine and standardized assessment of pain should be conducted in patients with conditions, such as Fabry disease, that are associated with chronic pain. Such pain assessments, using validated and reliable pain scales or questionnaires, should cover the severity, location, temporal pattern and quality of the pain and how the pain impacts on quality of life and normal daily activity. The severity or intensity of pain can be assessed on verbal descriptor scales, visual analogue scales and numerical rating scales, which rate pain on a scale from 'no pain' through to 'excruciating pain' or pain as bad as you can imagine'. Three pain questionnaires that include such rating scales are short enough to be used repeatedly in a clinical or research setting: the Memorial Pain Assessment Card, the McGill Pain Questionnaire and the Brief Pain Inventory (BPI). The BPI also measures the effect of pain on daily activity and quality of life, defines the location of pain and assesses the effectiveness of previous pain relief medication.
Conclusions: Reliable instruments are available to assess pain in chronic disease. In Fabry disease, these should be used routinely to aid decisions concerning analgesic/pain control medication and to assess the effect of enzyme replacement therapy.
Similar articles
-
Mechanisms of neuropathic pain and their importance in Fabry disease.Acta Paediatr Suppl. 2002;91(439):34-7. doi: 10.1111/j.1651-2227.2002.tb03107.x. Acta Paediatr Suppl. 2002. PMID: 12572840 Review.
-
A comprehensive Fabry-related pain questionnaire for adult patients.Pain. 2014 Nov;155(11):2301-5. doi: 10.1016/j.pain.2014.08.024. Epub 2014 Aug 26. Pain. 2014. PMID: 25168668
-
Pathophysiology and assessment of neuropathic pain in Fabry disease.Acta Paediatr Suppl. 2002;91(439):48-52. doi: 10.1111/j.1651-2227.2002.tb03110.x. Acta Paediatr Suppl. 2002. PMID: 12572843 Review.
-
Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).J Med Genet. 2005 Mar;42(3):247-52. doi: 10.1136/jmg.2004.025791. J Med Genet. 2005. PMID: 15744039 Free PMC article.
-
The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients.J Pain Symptom Manage. 2002 Nov;24(5):517-25. doi: 10.1016/s0885-3924(02)00526-2. J Pain Symptom Manage. 2002. PMID: 12547051
Cited by
-
Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience.JIMD Rep. 2012;3:33-43. doi: 10.1007/8904_2011_44. Epub 2011 Sep 15. JIMD Rep. 2012. PMID: 23430871 Free PMC article.
-
Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.J Inherit Metab Dis. 2018 Sep;41(5):829-838. doi: 10.1007/s10545-017-0123-6. Epub 2018 Jan 5. J Inherit Metab Dis. 2018. PMID: 29305734 Free PMC article. Clinical Trial.
-
Social-adaptive and psychological functioning of patients affected by Fabry disease.J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S73-81. doi: 10.1007/s10545-009-9025-6. Epub 2010 Jan 20. J Inherit Metab Dis. 2010. PMID: 20087663
-
Health-related quality of life in Norwegian adults with Fabry disease: Disease severity, pain, fatigue and psychological distress.JIMD Rep. 2021 Jul 16;62(1):56-69. doi: 10.1002/jmd2.12240. eCollection 2021 Nov. JIMD Rep. 2021. PMID: 34765399 Free PMC article.
-
Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan.J Patient Rep Outcomes. 2022 Nov 17;6(1):115. doi: 10.1186/s41687-022-00525-z. J Patient Rep Outcomes. 2022. PMID: 36394676 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
